Details of the Drug Formulations

General Information of Drug (ID: DM2C4RF)

Drug Name
BETRIXABAN Drug Info
Synonyms
Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3
Indication
Disease Entry ICD 11 Status REF
Venous thromboembolism BD72 Approved [1]
Cerebrovascular ischaemia 8B1Z Phase 3 [2]
Cross-matching ID
PubChem CID
10275777
ChEBI ID
CHEBI:140421
CAS Number
330942-05-7
TTD ID
D0J0BU
VARIDT ID
DR00216
ACDINA ID
D00067

Full List of Drug Formulations Containing This Drug

Betrixaban 80 mg capsule
Company Formulation ID FDA Description
Portola Pharmaceuticals F02505 Dextrose monohydrate; Fd&c blue no. 1; Magnesium stearate; Ferric oxide yellow; Ferrosoferric oxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified
------------------------------------------------------------------------------------
Betrixaban 40 mg capsule
Company Formulation ID FDA Description
Portola Pharmaceuticals F02504 Dextrose monohydrate; Fd&c blue no. 1; Magnesium stearate; Ferrosoferric oxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 ClinicalTrials.gov (NCT01583218) Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study). U.S. National Institutes of Health.